Boston Scientific Delivers Q2 Beat with $5.44B Revenue, Cuts 2026 Guidance

BSX reported Q2 2026 net sales of $5.44 billion, up 7.5% on a reported basis and 7.0% organically, with adjusted EPS of $0.86 beating the $0.83 consensus by $0.03.

Despite the beat, Boston Scientific cut its full-year 2026 outlook. It now guides to reported net sales growth of 5.5% to 6.5% and organic growth of 5% to 6%, down from the 7.0% to 8.5% reported and 6.5% to 8% organic range set after Q1, with adjusted EPS narrowed to $3.28 to $3.32. Management cited softening demand in the WATCHMAN stroke-prevention franchise, U.S. electrophysiology, and urology, plus tariff costs and macro uncertainty.

The quarter included about $80 million in refunds on previously paid IEEPA tariffs, while gross margin absorbed inventory charges tied to discontinuing the PolarX cryoablation system. Segment growth stayed uneven: Cardiovascular sales rose 8.3% versus 5.9% for MedSurg, and positive CHAMPION-AF and FARAPULSE trial data offered a partial counterweight to the WATCHMAN and EP softness.

Shares rose more than 3% in premarket trading on the beat, though gains narrowed as investors weighed the guidance cut against continued pressure in two core franchises. Watch whether WATCHMAN volumes stabilize and how tariff exposure evolves in the second half, the two factors management cited as driving the revised range.

Related Stocks

• BSX
• FDS